Table 2.
Overview of ongoing (actively recruiting) phase II and III trials of bevacizumab in NSCLCa
| Phase | Trial description | Identifier number |
|---|---|---|
| Early-stage NSCLC | ||
| II | Neoadjuvant bevacizumab in combination with cisplatin-based chemotherapy versus neoadjuvant cisplatin and docetaxel, both followed by adjuvant bevacizumab, in patients with Stage IB-IIIA NSCLC undergoing surgical resection. | NCT00130780 |
| II | Neoadjuvant bevacizumab in combination with carboplatin and paclitaxel in patients with Stage IB-IIA NSCLC undergoing surgical resection. | NCT00960297 |
| II | Neoadjuvant bevacizumab in combination with cisplatin and gemcitabine, followed by cisplatin and etoposide after surgical resection, in patients with Stage IIIA NSCLC. | NCT00924209 |
| II | Adjuvant bevacizumab in combination with carboplatin and docetaxel, followed by maintenance bevacizumab and erlotinib, in patients with surgically resected Stage IB-IIIA NSCLC. | NCT00621049 |
| III | Adjuvant bevacizumab in combination with chemotherapy versus chemotherapy alone in patients with surgically resected Stage IB-IIIA NSCLC. | NCT00324805 |
| First-line in advanced NSCLC | ||
| II | Bevacizumab in combination with carboplatin and gemcitabine. | NCT00150657 |
| II | Bevacizumab in combination with carboplatin and gemcitabine. | NCT00400803 |
| II | Bevacizumab in combination with carboplatin and abraxane. | NCT00642759 |
| II | Bevacizumab in combination with carboplatin, paclitaxel, and erlotinib. | NCT00550537 |
| II | Bevacizumab in combination with carboplatin, paclitaxel, and imprime PGG® injection. | NCT00874107 |
| II | Bevacizumab in combination with paclitaxel and gemcitabine. | NCT00655850 |
| II | Bevacizumab in combination with docetaxel in patients aged >75 years. | NCT00541099 |
| II | Bevacizumab in combination with gemcitabine and cisplatin versus bevacizumab in combination with gemcitabine in patients aged .70 years. | NCT01077713 |
| II | Bevacizumab in combination with platinum-based chemotherapy versus bevacizumab in combination with erlotinib. | NCT00531960 |
| II | Bevacizumab in combination with carboplatin and paclitaxel versus bevacizumab in combination with carboplatin, paclitaxel, and erlotinib in nonsmokers. | NCT00976677 |
| II | Bevacizumab in combination with carboplatin and paclitaxel versus bevacizumab in combination with carboplatin, paclitaxel, and cixutumumab. | NCT00955305 |
| II | Bevacizumab in combination with carboplatin and paclitaxel, versus CT-322 in combination with carboplatin and paclitaxel. | NCT00850577 |
| II | Bevacizumab in combination with carboplatin and paclitaxel, or second-line bevacizumab in combination with erlotinib, in patients with asymptomatic untreated brain metastases. | NCT00800202 |
| II | Bevacizumab in combination with pemetrexed. | NCT00254319 |
| II | Bevacizumab in combination with paclitaxel and pemetrexed. | NCT00807573 |
| II | Bevacizumab in combination with carboplatin and pemetrexed. | NCT00614822 |
| II | Bevacizumab in combination with carboplatin and pemetrexed in patients with ECOG performance status 2. | NCT00892710 |
| II | Bevacizumab in combination with cisplatin and pemetrexed. | NCT00998166 |
| II | Bevacizumab in combination with gemcitabine and pemetrexed. | NCT00438204 |
| II | Bevacizumab in combination with erlotinib in patients aged ≥70 years. | NCT00553800 |
| II | Bevacizumab in combination with cisplatin and pemetrexed versus bevacizumab in combination with erlotinib. | NCT01116219 |
| II | Bevacizumab in combination with cisplatin and pemetrexed, followed by maintenance bevacizumab and pemetrexed. | NCT01004250 |
| II | Bevacizumab in combination with carboplatin and gemcitabine, followed by bevacizumab in combination with erlotinib at disease progression. | NCT00702975 |
| II | Bevacizumab in combination with carboplatin and docetaxel, followed by second-line bevacizumab and pemetrexed or second-line pemetrexed alone. | NCT00766246 |
| III | Carboplatin and paclitaxel with or without bevacizumab versus carboplatin, paclitaxel, and cetuximab with or without bevacizumab. | NCT00946712 |
| III | Bevacizumab in combination with pemetrexed, versus bevacizumab alone and pemetrexed alone. | NCT01107626 |
| III | Bevacizumab in combination with pemetrexed and carboplatin versus bevacizumab in combination with pemetrexed in patients aged >65 years. | NCT00976456 |
| III | Bevacizumab in combination with cisplatin and pemetrexed, followed by maintenance bevacizumab and pemetrexed, versus maintenance bevacizumab alone. | NCT00961415 |
| III | Bevacizumab in combination with carboplatin and pemetrexed, followed by maintenance bevacizumab and pemetrexed, versus first-line bevacizumab in combination with carboplatin and paclitaxel, followed by maintenance bevacizumab. | NCT00762034 |
| III | Bevacizumab in combination with carboplatin and paclitaxel, followed by maintenance bevacizumab, versus first-line pemetrexed in combination with carboplatin, followed by maintenance pemetrexed. | NCT00948675 |
| Second- or third-line in advanced NSCLC | ||
| II | Second- or third-line bevacizumab in combination with carboplatin and paclitaxel. | NCT00753909 |
| II | Second-line bevacizumab in combination with vinorelbine. | NCT00755170 |
| II | Second-line bevacizumab in combination with docetaxel. | NCT00741195 |
| II | Second-line bevacizumab in combination with pemetrexed. | NCT00741221 |
| II | Second-line bevacizumab in combination with pemetrexed versus pemetrexed alone. | NCT00735891 |
| II | Second-line bevacizumab in combination with erlotinib. | NCT00749567 |
| II | Second-line bevacizumab in combination with erlotinib. | NCT00436332 |
| II | Second-line bevacizumab in combination with ixabepilone. | NCT01057212 |
a
ClinicalTrials.gov accessed on November 22, 2010.
Abbreviations. ECOG: Eastern Cooperative Oncology Group; NSCLC: non-small cell lung cancer.